| References: |
L-701,324 is a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats. L-701,324 exhibits a beneficial action in the animal model of parkinsonian rigidity, but not that of parkinsonian akinesia.L-701,324 (2.5-40 mg/kg IP) dose-dependently decreased the muscle tone enhanced by haloperidol (1-5 mg/kg IP). Likewise, the haloperidol-enhanced resting EMG activity and the EMG reflex response to passive movements were diminished by lower and almost abolished by higher doses of L-701,324. However, up to a dose of 20 mg/kg IP, L-701,324 did not influence haloperidol (0.5 mg/kg IP)-induced catalepsy. Moreover, L-701,324 (1.25-5 mg/kg IP) given alone or together with haloperidol (0.5-1 mg/kg IP) disturbed rotarod performance. Gross observation of behaviour indicated that rats injected with L-701,324 in doses equal to or higher than 5 mg/kg, alone or in combination with haloperidol, were markedly ataxic, i.e. rats showed signs of disturbed balance and loss of control over their hind limbs. For the detailed information of L-701,324, the solubility of L-701,324 in water, the solubility of L-701,324 in DMSO, the solubility of L-701,324 in PBS buffer, the animal experiment (test) of L-701,324, the cell expriment (test) of L-701,324, the in vivo, in vitro and clinical trial test of L-701,324, the EC50, IC50,and affinity,of L-701,324, For the detailed information of L-701,324, the solubility of L-701,324 in water, the solubility of L-701,324 in DMSO, the solubility of L-701,324 in PBS buffer, the animal experiment (test) of L-701,324, the cell expriment (test) of L-701,324, the in vivo, in vitro and clinical trial test of L-701,324, the EC50, IC50,and affinity,of L-701,324, Please contact DC Chemicals. |
